Alerta De Seguridad para cobas EGFR Mutation Test, v2 CE- IVD and cobas cfDNA Sample Preparation Kit

Según Department of Health, este evento ( alerta de seguridad ) involucró a un dispositivo médico en Hong Kong que fue producido por Roche Diagnostics.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • Fecha
    2016-04-18
  • Fecha de publicación del evento
    2016-04-18
  • País del evento
  • Fuente del evento
    DH
  • URL de la fuente del evento
  • Notas / Alertas
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • Notas adicionales en la data
    Medical Device Safety Alert
  • Causa
    Medical device safety alert: roche diagnostics cobas egfr mutation test, v2 ce- ivd and cobas cfdna sample preparation kit medical device manufacturer, roche diagnostics, has issued a medical device safety alert concerning its cobas egfr mutation test, v2 ce- ivd and cobas cfdna sample preparation kit. according to the manufacturer, several mutations (l858r, exon 19 deletion, t790m) inconsistently generated “no mutation detected” (i.E. false negative) results with the cobas egfr mutation test, v2 when utilising the cobas cfdna sample preparation kit during internal studies using contrived plasma specimens. there is no impact when using the cobas dna sample preparation kit with the cobas egfr mutation test, v2 to test formalin-fixed paraffin-embedded tumour (ffpet) tissue samples. patients with a false negative result for the mutations may be denied the prospect of prolongation of disease control and survival (8-12 months). the manufacturer will update the instructions for use (ifu) for the cobas egfr mutation test, v2 and cobas cfdna sample preparation kit to revise the handling of the eluate for plasma specimens prior to amplification and detection. users are advised to follow the revised instruction until the updated ifu become available. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 18 april 2016.

Device

  • Modelo / Serial
  • Descripción del producto
    Medical Device Safety Alert: Roche Diagnostics cobas EGFR Mutation Test, v2 CE- IVD and cobas cfDNA Sample Preparation Kit
  • Manufacturer

Manufacturer